Insulet Corporation $PODD Stock Holdings Increased by Caisse DE Depot ET Placement DU Quebec

Key Points

• Caisse DE Depot ET Placement DU Quebec significantly increased its stake in Insulet Corporation by 169.1% in Q1, owning 43,372 shares worth approximately $11.39 million.
• Insulet reported $1.17 EPS for the quarter, exceeding analysts' expectations of $0.92, with a revenue of $649.1 million, marking a 32.9% year-over-year growth.
• Wall Street analysts are optimistic about Insulet, with an average price target of $332.71 and 16 analysts rating the stock as a Buy.

Caisse DE Depot ET Placement DU Quebec lifted its stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) by 169.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 43,372 shares of the medical instruments supplier's stock after acquiring an additional 27,254 shares during the period. Caisse DE Depot ET Placement DU Quebec owned 0.06% of Insulet worth $11,390,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in PODD. Dimensional Fund Advisors LP boosted its stake in Insulet by 42.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 289,507 shares of the medical instruments supplier's stock worth $75,588,000 after buying an additional 86,505 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Insulet by 0.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 202,728 shares of the medical instruments supplier's stock worth $52,927,000 after buying an additional 744 shares during the last quarter. Integrated Wealth Concepts LLC boosted its stake in Insulet by 39.1% in the 4th quarter. Integrated Wealth Concepts LLC now owns 3,562 shares of the medical instruments supplier's stock worth $930,000 after buying an additional 1,001 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Insulet in the 4th quarter worth about $371,000. Finally, Northern Trust Corp boosted its stake in Insulet by 20.5% in the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier's stock worth $192,881,000 after buying an additional 125,710 shares during the last quarter.

Analyst Ratings Changes

A number of equities analysts have recently commented on PODD shares. Barclays raised their price objective on Insulet from $266.00 to $300.00 and gave the stock an "equal weight" rating in a report on Thursday, August 21st. Oppenheimer raised their price objective on Insulet from $312.00 to $324.00 and gave the stock an "outperform" rating in a report on Friday, May 9th. Wall Street Zen upgraded Insulet from a "hold" rating to a "buy" rating in a report on Saturday, August 9th. Truist Financial began coverage on Insulet in a report on Monday, June 16th. They issued a "buy" rating and a $365.00 price objective on the stock. Finally, Raymond James Financial reiterated an "outperform" rating and set a $360.00 target price (up from $328.00) on shares of Insulet in a report on Tuesday, May 27th. Sixteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Insulet presently has a consensus rating of "Moderate Buy" and a consensus price target of $332.71.

Insulet Stock Up 0.7%

PODD stock traded up $2.28 during midday trading on Monday, hitting $339.88. 515,158 shares of the company's stock were exchanged, compared to its average volume of 702,791. The stock has a market capitalization of $23.93 billion, a price-to-earnings ratio of 103.31, a price-to-earnings-growth ratio of 2.85 and a beta of 1.36. The firm has a 50 day moving average price of $304.04 and a 200-day moving average price of $287.71. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $199.68 and a 12-month high of $341.14.

Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. The company had revenue of $649.10 million during the quarter, compared to analyst estimates of $612.31 million. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The business's revenue was up 32.9% on a year-over-year basis. During the same quarter last year, the firm earned $0.55 EPS. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts anticipate that Insulet Corporation will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.